MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure
2017 ◽
Vol 66
(1)
◽
pp. S83-S84
◽
Keyword(s):
2016 ◽
Vol 51
(7)
◽
pp. 741-747
◽
Keyword(s):
2016 ◽
Vol 19
(12)
◽
pp. 1144-1156
◽